Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies

2875 - A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 Trial


21 Oct 2018


Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies


Cytotoxic Therapy;  Immunotherapy

Tumour Site


Jean-Louis Pujol


Annals of Oncology (2018) 29 (suppl_8): viii596-viii602. 10.1093/annonc/mdy298


J. Pujol1, L. Greillier2, C. Audigier Valette3, D. Moro-Sibilot4, L. Uwer5, J. Hureaux6, L. Thiberville7, D. Carmier8, J. Madelaine9, J. Otto10, V. Gounant11, P. Merle12, P. Mourlanette13, O. Molinier14, P.A. Renault15, J. Mazieres16, M. Antoine17, A. Langlais18, F. Morin18, P. Souquet19

Author affiliations

  • 1 Pneumologie, Hopital Arnaud de Villeneuve, 34295 - Montpellier/FR
  • 2 Department Of Multidisciplinary Oncology And Therapeutic Innovations, Assistance Publique Hopitaux de Marseille, 13015 - Marseille/FR
  • 3 Pneumologie, Hospital Sainte Musse, 83100 - Toulon/FR
  • 4 Pneumologie, CHU Grenoble-Alpes, Grenoble/FR
  • 5 N/a, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 6 Pneumologie, CHU Angers, 49933 - Angers/FR
  • 7 Pneumologie, CHU Hôpitaux de Rouen-Charles Nicolle, 76031 - Rouen/FR
  • 8 Pneumologie, CHRU Bretonneau, 37044 - Tours/FR
  • 9 Pneumologie, CHU de Caen, 14033 - Caen/FR
  • 10 N/a, Centre Antoine Lacassagne, Nice/FR
  • 11 Pneumologie, Hopital Bichat Claude Bernard, 75018 - Paris/FR
  • 12 Pneumologie, CHU, 63011 - Clermont-Ferrand/FR
  • 13 Pneumologie, Clinique des Cedres, Cornebarrieu/FR
  • 14 Pneumologie, Centre Hospitalier Du Mans, 72037 - Le Mans/FR
  • 15 Pneumologie, Centre Hospitalier, Pau/FR
  • 16 Thoracic Oncology, Hospital Larrey, 31400 - Toulouse/FR
  • 17 Pathology, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 18 Clinical research Unit, French Cooperative Thoracic Intergroup, 75009 - Paris/FR
  • 19 Pneumologie, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2875


This randomized Phase II trial sought to evaluate the activity of the engineered PD-L1 antibody ATEZOLIZUMAB (ATZ), as systemic therapy of small cell lung cancer (SCLC) progressing after first line platinum – ETOPOSIDE based chemotherapy (CT).


Patients (pts) were randomly assigned 2:1 to ATZ, 1200 mg IV, every three weeks until progression or unacceptable toxicity, or conventional CT up to six cycles: i.e. second-line oral or IV TOPOTECAN or re-induction of CARBOPLATIN – ETOPOSIDE doublet (investigator choice based on center policy). Main eligibility criteria were performance status (PS) 0-2 and measurable disease (RECIST 1.1). We performed no selection on PD-L1 tissue expression. Patients receiving corticosteroid therapy, pts with autoimmune disease history and these with brain metastases were excluded. The primary endpoint was objective response rate (ORR) at 6 weeks (confirmation needed at 12 weeks).


A total of 73 patients were randomized (ATZ n = 49; CT n = 24) between 03/2017 and 12/2017. One patient in the ATZ group did not receive any treatment. In the ATZ group, 83.7 % of the pts had PS 0-1, 79.6% had an extensive disease and 67.3 % had a sensitive relapse (progression after 90 days since the last dose of first line CT). At six weeks, in the ATZ group and eligible pts (n = 43), ORR was observed in 1 pt (2.3%, CI [0.0; 6.8]) and 8 other pts (18.6%, CI [7.0; 30.2]) had a stable disease. In the CT group and eligible pts (n = 21), 9.5% of the pts achieved an ORR and 52.4% had a stable disease. Progression-free survival were 1.4 months, CI [1.2; 1.5] in the ATZ group and 4.2 months CI [1.5; 5.9] in the CT group. At the time of reporting, 5 pts still benefit from a stable disease in the ATZ group versus none in the CT group. Two pts (4.2%) in the ATZ group experienced a grade 3 fatigue. Two pts developed grade 1 dysthyroidism.


IFCT-1603 trial did not show any efficacy or safety signals for single drug ATEZOLIZUMAB used as treatment in relapsed SCLC. Follow-up data will be updated and search for PD-L1 tissue expression and mutational tumor burden will be presented.

Clinical trial identification


Legal entity responsible for the study

IFCT (French Cooperative Thoracic Intergroup).



Editorial Acknowledgement



L. Greillier: Grants, personal fees and non-financial support: Roche, outside the submitted work. C. Audigier Valette: Roche. D. Moro-Sibilot: Advisory board: Roche, Pfizer, AstraZeneca, BMS, MSD, Lilly, Boehringer, Abbvie, Takeda; Corporate-sponsored research: Boehringer Ingelheim, Abbvie. V. Gounant: AstraZeneca, Roche, Boehringer Ingelheim, BMS, Pfizer, Abbvie, MSD. P-J. Souquet: Grant, personnal fees, congress, board: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.